Hyderabad-based Natco Pharma Limited announced that its product 'ondansetron' tablets has approved by the Canadian regulatory agency (TPD-Health Canada).
The drug is in 4 mg and 8 mg tablets. In a statement, Natco Pharma Limited company secretary and general manager M Adinarayana Rao said the approval was accorded to Natco's marketing partner 'IP Generics' based in Canada. The drug is 'anti-emetic' and is used mainly during surgeries and chemo therapy.
No comments:
Post a Comment